860 related articles for article (PubMed ID: 30717773)
1. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
2. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
3. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
4. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
5. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
6. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
7. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
[No Abstract] [Full Text] [Related]
8. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
Staquicini FI; Hajitou A; Driessen WH; Proneth B; Cardó-Vila M; Staquicini DI; Markosian C; Hoh M; Cortez M; Hooda-Nehra A; Jaloudi M; Silva IT; Buttura J; Nunes DN; Dias-Neto E; Eckhardt B; Ruiz-Ramírez J; Dogra P; Wang Z; Cristini V; Trepel M; Anderson R; Sidman RL; Gelovani JG; Cristofanilli M; Hortobagyi GN; Bhujwalla ZM; Burley SK; Arap W; Pasqualini R
Elife; 2021 Jun; 10():. PubMed ID: 34060472
[TBL] [Abstract][Full Text] [Related]
9. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
10. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
11. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
12. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
14. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
16. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
Cha JH; Chan LC; Wang YN; Chu YY; Wang CH; Lee HH; Xia W; Shyu WC; Liu SP; Yao J; Chang CW; Cheng FR; Liu J; Lim SO; Hsu JL; Yang WH; Hortobagyi GN; Lin C; Yang L; Yu D; Jeng LB; Hung MC
J Biol Chem; 2022 Apr; 298(4):101817. PubMed ID: 35278434
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
18. Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer.
David T; Mallavialle A; Faget J; Alcaraz LB; Lapierre M; du Roure PD; Laurent-Matha V; Mansouri H; Jarlier M; Martineau P; Roger P; Guiu S; Chardès T; Liaudet-Coopman E
Br J Pharmacol; 2023 Nov; ():. PubMed ID: 38030588
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
[TBL] [Abstract][Full Text] [Related]
20. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
